Drug Profile
Research programme: LHRH peptidomimetic antagonists - AEterna Zentaris
Alternative Names: AEZS-115; LHRH peptidomimetics - AEterna Zentaris/Solvay; ZEN-019Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AEterna Zentaris Inc; Solvay Pharmaceuticals
- Developer AEterna Zentaris Inc
- Class
- Mechanism of Action Gonadotropin releasing hormone inhibitors; LHRH receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Cancer; Endometriosis
- Discontinued Endocrine disorders; Genitourinary disorders; Pregnancy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in Europe (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Europe (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Endometriosis in Europe (PO)